An FGFR4 polymorphism is implicated in the progression of neuroendocrine tumors

被引：0
|
作者：
Serra, S. [1 ]
Zheng, L. [1 ]
Chetty, R. [1 ]
Ezzat, S. [1 ]
Asa, S. L. [1 ]
机构：
[1] UHN, Dept Pathol, Toronto, ON, Canada
来源：
VIRCHOWS ARCHIV | 2009年 / 455卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：41 / 41
页数：1
相关论文
共 50 条
  • [21] Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas
    Mawrin, Christian
    Kirches, Elmar
    Diete, Sabine
    Wiedemann, Falk R.
    Schneider, Thomas
    Firsching, Raimund
    Kropf, Siegfried
    Bogerts, Bernhard
    Vorwerk, Christian K.
    Kruger, Sabine
    Dietzmann, Knut
    CANCER LETTERS, 2006, 239 (02) : 239 - 245
  • [22] FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan
    Li, Ju-Pi
    Huang, Hsien-Cheng
    Yang, Po-Jen
    Chang, Chien-Yuan
    Chao, Yu-Hua
    Tsao, Thomas Chang-Yao
    Huang, Hsuan
    Hung, Yu-Ching
    Hsieh, Ming-Ju
    Yang, Shun-Fa
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (16) : 1 - 11
  • [23] EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma
    Shen, Bin
    Shi, Jue-Ping
    Zhu, Zhi-Xuan
    He, Zhi-Dong
    Liu, Shen-Yan
    Shi, Wan
    Zhang, Yong-Xian
    Ying, Hai-Yan
    Wang, Jie
    Xu, Rui-Feng
    Fang, Fei
    Chang, Harrison Xuesong
    Chen, Zhui
    Zhang, Nan-Nan
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12) : 1479 - 1492
  • [24] Analysis of FGFR4 Locus Amplification in Pediatric and Adult Sporadic Adrenocortical Tumors.
    Ribeiro, T. C.
    Brito, L. P.
    Lerario, A. M.
    Mariani, B. M. P.
    Jorge, A. A.
    Fragoso, M. C.
    Mendonca, B. B.
    Latronico, A. C.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [25] First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
    Hagel, Margit
    Miduturu, Chandra
    Sheets, Michael
    Rubin, Nooreen
    Weng, Weifan
    Stransky, Nicolas
    Bifulco, Neil
    Kim, Joseph L.
    Hodous, Brian
    Brooijmans, Natasja
    Shutes, Adam
    Winter, Christopher
    Lengauer, Christoph
    Kohl, Nancy E.
    Guzi, Timothy
    CANCER DISCOVERY, 2015, 5 (04) : 424 - 437
  • [26] FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men
    Ho, C. K. M.
    Anwar, S.
    Nanda, J.
    Habib, F. K.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2010, 13 (01) : 94 - 96
  • [27] FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex
    Sugiyama, Nami
    Varjosalo, Markku
    Meller, Pipsa
    Lohi, Jouko
    Chan, Kui Ming
    Zhou, Zhongjun
    Alitalo, Kari
    Taipale, Jussi
    Keski-Oja, Jorma
    Lehti, Kaisa
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (36) : 15786 - 15791
  • [28] FIRST SELECTIVE SMALL MOLECULE INHIBITOR OF FGFR4 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS WITH AN ACTIVATED FGFR4 SIGNALING PATHWAY
    Hoeflich, K.
    Hagel, M.
    Miduturu, C.
    Sheets, M.
    Rubin, N.
    Weng, W.
    Stransky, N.
    Bifulco, N.
    Kim, J.
    Hodous, B.
    Brooijmans, N.
    Shutes, A.
    Winter, C.
    Lengauer, C.
    Kohl, N.
    Guzi, T.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S215 - S216
  • [29] 靶向FGFR4的miRNA筛选
    高赢政
    蔡琳
    黄佳伟
    邱梦媛
    黄通周
    数理医药学杂志, 2017, 30 (06) : 791 - 794
  • [30] FGFR3 and FGFR4 mutational analyses in thyroid carcinoma
    Serra, S.
    Cheng, S.
    Ezzat, S.
    Asa, S. L.
    LABORATORY INVESTIGATION, 2008, 88 : 110A - 111A
12345